For patients, payers, and health systems, the triple-agonist era does not eliminate bariatric surgery - it creates a new category of patients who can access surgical-equivalent weight loss without surgical risk, provided they remain on drug and access it at a price their payer will cover
Research suggests that higher doses of semaglutide can produce significant weight loss in people with obesity
The hydrochloride salt of L-Arginine confers improved solubility and stability to the amino acid, making it highly water-soluble and easy to incorporate into various supplement formulations and medical preparations
This side effect doesn't occur with CagriSema or semaglutide
If 10% of the target population (an estimated 360,000 people) uses Wegovy for a full year, that would amount to additional net Medicare Part D spending of $2.8 billion for one year for this one drug alone
thus, we proceeded with the analysis using the sample in LMNG